Apellis Pharmaceuticals (NASDAQ:APLS) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) posted its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03, Briefing.com reports. The business had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm’s quarterly revenue was up 110.2% compared to the same quarter last year. During the same quarter last year, the business earned ($1.02) earnings per share.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $36.56 on Monday. The stock has a market capitalization of $4.44 billion, a PE ratio of -10.56 and a beta of 0.88. Apellis Pharmaceuticals has a 1-year low of $19.83 and a 1-year high of $73.80. The firm has a fifty day simple moving average of $39.20 and a 200 day simple moving average of $50.64. The company has a current ratio of 5.08, a quick ratio of 3.02 and a debt-to-equity ratio of 1.73.

Insider Buying and Selling

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at approximately $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the sale, the director now directly owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total value of $3,341,711.45. Following the transaction, the insider now directly owns 1,115,983 shares in the company, valued at $47,261,880.05. The disclosure for this sale can be found here. 6.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

APLS has been the topic of several research analyst reports. Robert W. Baird reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, July 23rd. Wedbush decreased their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a report on Friday. Citigroup reduced their price target on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, The Goldman Sachs Group dropped their price objective on shares of Apellis Pharmaceuticals from $77.00 to $66.00 and set a “buy” rating on the stock in a report on Friday. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $73.50.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).